These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22044409)

  • 41. Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder.
    Kato T; Miura M; Kishikawa H; Nishimura K; Satoh S; Ichikawa Y
    Transplantation; 2011 Jul; 92(2):e8-9. PubMed ID: 21747275
    [No Abstract]   [Full Text] [Related]  

  • 42. Role of pharmacogenomics in dialysis and transplantation.
    Birdwell K
    Curr Opin Nephrol Hypertens; 2014 Nov; 23(6):570-7. PubMed ID: 25162201
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review.
    Hussaini SA; Waziri B; Dickens C; Duarte R
    Pharmacogenomics; 2024; 25(7):329-341. PubMed ID: 39109483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tacrolimus pharmacogenetics: bringing the laboratory into the clinic.
    McLaren A
    Transplantation; 2003 Dec; 76(11):1541-2. PubMed ID: 14705621
    [No Abstract]   [Full Text] [Related]  

  • 45. How calcineurin inhibitors cause hypertension.
    Luft FC
    Nephrol Dial Transplant; 2012 Feb; 27(2):473-5. PubMed ID: 22172729
    [No Abstract]   [Full Text] [Related]  

  • 46. Update on the clinical pharmacogenomics of organ transplantation.
    Burckart GJ; Amur S
    Pharmacogenomics; 2010 Feb; 11(2):227-36. PubMed ID: 20136361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The future of research into genetics and the precision dosing of tacrolimus: what do we need to know?
    Zhu J; Pasternak AL; Crona DJ
    Pharmacogenomics; 2020 Oct; 21(15):1061-1064. PubMed ID: 32896220
    [No Abstract]   [Full Text] [Related]  

  • 48. Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients.
    Koefoed-Nielsen PB; Jørgensen KA
    Transplant Proc; 2002 Aug; 34(5):1743-4. PubMed ID: 12176559
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of calcineurin inhibitors on QT dispersion in renal transplant recipients.
    Türkmen A; Bunyak B; Oflaz H; Kücük M; Sahin S; Bugra Z; Umman B; Sever MS
    Transplant Proc; 2002 Nov; 34(7):2996-8. PubMed ID: 12431681
    [No Abstract]   [Full Text] [Related]  

  • 50. A taste of individualized medicine: physicians' reactions to automated genetic interpretations.
    Lærum H; Bremer S; Bergan S; Grünfeld T
    J Am Med Inform Assoc; 2014 Feb; 21(e1):e143-6. PubMed ID: 24001515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics in transplant patients: mind the mix.
    Ten Brink MH; van der Straaten T; Bouwsma H; Baak-Pablo R; Guchelaar HJ; Swen JJ
    Clin Pharmacol Ther; 2013 Oct; 94(4):443-4. PubMed ID: 23708744
    [No Abstract]   [Full Text] [Related]  

  • 52. Insights into pharmacogenomics and its impact upon immunosuppressive therapy.
    Yagil Y; Yagil C
    Transpl Immunol; 2002 May; 9(2-4):203-9. PubMed ID: 12180832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overview of pharmacogenetics.
    Katz DA
    Curr Protoc Pharmacol; 2007 Mar; Chapter 6():Unit6.10. PubMed ID: 21948170
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacogenomics: personalizing pediatric heart transplantation.
    Van Driest SL; Webber SA
    Circulation; 2015 Feb; 131(5):503-12. PubMed ID: 25645611
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacogenetics and pharmacogenomics.
    Pirmohamed M
    Br J Clin Pharmacol; 2001 Oct; 52(4):345-7. PubMed ID: 11678777
    [No Abstract]   [Full Text] [Related]  

  • 56. Predictive ability of direct-to-consumer pharmacogenetic testing: when is lack of evidence really lack of evidence?
    Kalf RR; Bakker R; Janssens AC
    Pharmacogenomics; 2013 Mar; 14(4):341-4. PubMed ID: 23438877
    [No Abstract]   [Full Text] [Related]  

  • 57. CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.
    Chen L; Prasad GVR
    Pharmgenomics Pers Med; 2018; 11():23-33. PubMed ID: 29563827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
    Meng XG; Guo CX; Feng GQ; Zhao YC; Zhou BT; Han JL; Chen X; Shi Y; Shi HY; Yin JY; Peng XD; Pei Q; Zhang W; Wang G; He M; Liu M; Yang JK; Zhou HH
    Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Future of the pharmacogenomics of calcineurin inhibitors in renal transplant patients.
    Zhu H; Ge W
    Pharmacogenomics; 2011 Nov; 12(11):1505-8. PubMed ID: 22044409
    [No Abstract]   [Full Text] [Related]  

  • 60. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
    de Jonge H; de Loor H; Verbeke K; Vanrenterghem Y; Kuypers DR
    Clin Pharmacol Ther; 2011 Sep; 90(3):414-22. PubMed ID: 21753749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.